from Viemed Healthcare, Inc. (NASDAQ:VMD)
Viemed Healthcare Announces Third Quarter 2025 Financial Results
LAFAYETTE, LA / ACCESS Newswire / November 5, 2025 / Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, announced today that it has reported its financial results for the three and nine months ended September 30, 2025.
Operational highlights (all dollar amounts are USD):
Net revenues for the quarter ended September 30, 2025 were $71.9 million, setting a Company record, representing an increase of $13.9 million, or 24.0%, over net revenues reported for the comparable quarter ended September 30, 2024.
Net income attributable to Viemed for the quarter ended September 30, 2025 totaled $3.5 million, or $0.09 per diluted share.
Adjusted EBITDA for the quarter ended September 30, 2025 totaled $16.1 million, a 15.5% increase as compared to the quarter ended September 30, 2024.
Net cash provided by operating activities totaled $18.4 million for the quarter and $48.5 million for the trailing twelve months ended September 30, 2025. Free cash flow totaled $12.4 million for the quarter and $23.3 million for the trailing twelve months ended September 30, 2025.
On July 1, 2025, Viemed closed on the strategic acquisition of Lehan's Medical Equipment ("Lehan"). The results of Lehan's operations have been included in the consolidated financial statements since the date of acquisition and were immediately accretive to net income and earnings per share.
During the third quarter of 2025, the Company repurchased and cancelled 1,706,380 common shares under its share repurchase program at a cost of $11.4 million, representing an average buyback price of $6.68 per share.
The Company increased its ventilator patient count to 12,372 as of September 30, 2025, an increase of 8.8% over September 30, 2024, and a 1.8% sequential increase from June 30, 2025.
The Company increased its PAP therapy patient count to 31,891 as of September 30, 2025, an increase of 63.7% over September 30, 2024, and a 21.4% sequential increase from June 30, 2025. The Company's sleep resupply patient count was 33,518 as of September 30, 2025, an increase of 51.4% over September 30, 2024, and a 32.8% sequential increase from June 30, 2025.
As of September 30, 2025, the Company maintains a strong cash balance of $11.1 million and an overall working capital balance of $5.8 million. Long term debt as of September 30, 2025 amounted to $19.6 million and the Company has $38 million available under existing credit facilities.
The Company is updating its financial guidance for the year ending December 31, 2025:
Net Revenue: Now expected to be in the range of $271 million to $273 million, compared to the previous guidance of $271 million to $277 million.
Adjusted EBITDA: Now expected to be in the range of $60 million to $62 million, compared to the previous guidance of $59 million to $62 million.
Casey Hoyt, Viemed's CEO, commented, "We delivered another outstanding quarter marked by strong execution and sustained expansion of our patient base across every major service line. Our disciplined approach to capital deployment was demonstrated through the full completion of our 2025 share repurchase program, while the acquisition of Lehan's Medical Equipment further enhanced our market presence and diversified our service capabilities. Both initiatives were accretive to earnings per share and reflect our unwavering commitment to creating long-term shareholder value while improving patient outcomes across the communities we serve."
"In addition, our strong liquidity and consistent free cash flow generation provide the flexibility to pursue strategic growth opportunities and return capital to shareholders, while preserving the financial strength that underpins our long-term success."
Conference Call Details
The Company will host a conference call to discuss third quarter results on Thursday, November 6, 2025, at 11:00 a.m. ET.
Interested parties may participate in the call by dialing:
877-407-6176 (US Toll-Free)
+1 201-689-8451 (International)
Live Audio Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=asCOlSnC
Following the conclusion of the call, an audio recording and transcript of the call can be accessed on the Company's website.
ABOUT VIEMED HEALTHCARE, INC.
Viemed is an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, including non-invasive ventilators (NIV), sleep therapy, staffing, and other complementary products and services. Viemed focuses on efficient and effective in-home treatment with clinical practitioners providing therapy, education and counseling to patients in their homes using high-touch and high-tech services. Visit our website at www.viemed.com.
For further information, please contact:
Investor Relations
Trae Fitzgerald
Chief Financial Officer
(337) 504-3802
Forward-Looking Statements
Certain statements contained in this press release may constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or "forward-looking information" as such term is defined in applicable Canadian securities legislation (collectively, "forward-looking statements"). Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "potential", "scheduled", "estimates", "forecasts", "intends", "anticipates", "believes", "projects", or the negatives thereof or variations of such words and phrases or statements that certain actions, events or results "will", "should", "may", "could", "would", "might" or "will be taken", "occur" or "be achieved" or the negative of these terms or comparable terminology. All statements other than statements of historical fact, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance, including the Company's net revenue and Adjusted EBITDA guidance for 2025, the anticipated synergies and other benefits of the acquisition of Lehan's Medical Equipment, future capital allocation priorities, liquidity position, free cash flow generation, and strategic growth opportunities, are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. Such statements reflect the Company's current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking statements to vary from those described herein should one or more of these risks or uncertainties materialize. These factors include, without limitation: the general business, market and economic conditions in the regions in which we operate; significant capital requirements and operating risks that we may be subject to; our ability to implement business strategies and pursue business opportunities; volatility in the market price of our common shares; the state of the capital markets; the availability of funds and resources to pursue operations; inflation; reductions in reimbursement rates and audits of reimbursement claims by various governmental and private payor entities; dependence on few payors; possible new drug discoveries; dependence on key suppliers; granting of permits and licenses in a highly regulated business; competition; disruptions in or attacks (including cyber-attacks) on our information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which we are exposed; difficulty integrating newly acquired businesses; the impact of new and changes to, or application of, current laws and regulations; the overall difficult litigation and regulatory environment; increased competition; increased funding costs and market volatility due to market illiquidity and competition for funding; critical accounting estimates and changes to accounting standards, policies, and methods used by us; and the occurrence of natural and unnatural catastrophic events or health epidemics or concerns, and claims resulting from such events or concerns, as well as other general economic, market and business conditions; and other factors beyond our control; as well as those risk factors discussed or referred to in the Company's disclosure documents filed with the U.S. Securities and Exchange Commission (the "SEC") available on the SEC's website at www.sec.gov, including the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and with the securities regulatory authorities in certain provinces of Canada available at www.sedar.com. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking statements prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking statements are expressly qualified in their entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking statements. The forward-looking statements included in this press release are made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law.
Use of Non-GAAP Financial Information and Financial Guidance
This press release includes references to financial measures that are calculated and presented using methodologies other than those in accordance with generally accepted accounting principles in the United States ("GAAP"), including Adjusted EBITDA and free cash flow. Any non-GAAP financial measures presented herein are intended to supplement, and not to be considered superior to or as a substitute for, the Company's consolidated financial statements prepared in accordance with GAAP. These non-GAAP financial measures exclude significant expense and income items required by GAAP, and are subject to inherent limitations, including the exercise of judgment by management regarding which items to exclude or include. Non-GAAP measures presented herein may not be comparable to similarly titled measures presented by other companies. The reconciliations of these non-GAAP measures to the most directly comparable GAAP measures are included in the tables accompanying this release.
This press release contains non-GAAP financial guidance. There is no reliable or reasonably estimable comparable GAAP measure for the Company's non-GAAP financial guidance because the Company is not able to reliably predict the impact of certain items that typically have one or more of the following characteristics: highly variable, difficult to project, unusual in nature, significant to the results of a particular period or not indicative of future operating results. Similar charges or gains were recognized in prior periods and will likely reoccur in future periods. As a result, reconciliation of the non-GAAP financial guidance to the most directly comparable GAAP measure is not available without unreasonable effort. In addition, the Company believes such a reconciliation would imply a degree of precision and certainty that could be confusing to investors. The variability of the specified items may have a significant and unpredictable impact on the Company's future GAAP results. The Company's financial guidance in this press release excludes the impact of potential future strategic acquisitions and any items that have not yet been identified or quantified. This guidance is subject to risks and uncertainties inherent in all forward-looking statements, as outlined above.
VIEMED HEALTHCARE, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Expressed in thousands of U.S. Dollars, except share amounts)
(Unaudited)
At September 30, 2025 | At December 31, 2024 | |||||||
ASSETS | ||||||||
Current assets | ||||||||
Cash and cash equivalents | $ | 11,123 | $ | 17,540 | ||||
Accounts receivable, net | 27,414 | 24,911 | ||||||
Inventory | 5,269 | 4,320 | ||||||
Income tax receivable | 1,913 | - | ||||||
Prepaid expenses and other assets | 4,265 | 6,109 | ||||||
Total current assets | $ | 49,984 | $ | 52,880 | ||||
Long-term assets | ||||||||
Property and equipment, net | 80,512 | 76,279 | ||||||
Finance lease right-of-use assets | - | 50 | ||||||
Operating lease right-of-use assets | 3,589 | 2,831 | ||||||
Equity investments | 2,794 | 2,794 | ||||||
Deferred tax asset | 5,669 | 8,398 | ||||||
Identifiable intangibles, net | 1,348 | 848 | ||||||
Goodwill | 58,464 | 32,989 | ||||||
Total long-term assets | $ | 152,376 | $ | 124,189 | ||||
TOTAL ASSETS | $ | 202,360 | $ | 177,069 | ||||
LIABILITIES | ||||||||
Current liabilities | ||||||||
Trade payables | $ | 8,670 | $ | 5,322 | ||||
Deferred revenue | 7,810 | 6,694 | ||||||
Income taxes payable | - | 3,883 | ||||||
Accrued liabilities | 25,007 | 20,157 | ||||||
Finance lease liabilities, current portion | - | 50 | ||||||
Operating lease liabilities, current portion | 1,149 | 811 | ||||||
Current portion of long-term debt | 1,554 | 409 | ||||||
Total current liabilities | $ | 44,190 | $ | 37,326 | ||||
Long-term liabilities | ||||||||
Accrued liabilities | 680 | 846 | ||||||
Operating lease liabilities, less current portion | 2,410 | 2,007 | ||||||
Long-term debt | 19,585 | 3,589 | ||||||
Total long-term liabilities | $ | 22,675 | $ | 6,442 | ||||
TOTAL LIABILITIES | $ | 66,865 | $ | 43,768 | ||||
Commitments and Contingencies | - | - | ||||||
SHAREHOLDERS' EQUITY | ||||||||
Common stock - No par value: unlimited authorized; 38,017,907 and 39,132,897 issued and outstanding as of September 30, 2025 and December 31, 2024, respectively | 16,901 | 23,365 | ||||||
Additional paid-in capital | 19,453 | 18,337 | ||||||
Retained earnings | 97,254 | 89,691 | ||||||
TOTAL VIEMED HEALTHCARE, INC.'S SHAREHOLDERS' EQUITY | $ | 133,608 | $ | 131,393 | ||||
Noncontrolling interest in subsidiary | 1,887 | 1,908 | ||||||
TOTAL SHAREHOLDERS' EQUITY | 135,495 | 133,301 | ||||||
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | $ | 202,360 | $ | 177,069 | ||||
VIEMED HEALTHCARE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Expressed in thousands of U.S. Dollars, except outstanding shares and per share amounts)
(Unaudited)
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||||||
Revenue | $ | 71,914 | $ | 58,004 | $ | 194,099 | $ | 163,562 | ||||||||
Cost of revenue | 30,569 | 23,633 | 82,744 | 66,497 | ||||||||||||
Gross profit | $ | 41,345 | $ | 34,371 | $ | 111,355 | $ | 97,065 | ||||||||
Operating expenses | ||||||||||||||||